Page last updated: 2024-09-26

intybin

Description

intybin: has both antimalarial and neuroprotective activities [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	174863
MeSH ID	M0041670

Synonym
intybin
[(3ar,4s,9as,9br)-4-hydroxy-6-methyl-3-methylidene-2,7-dioxo-4,5,9a,9b-tetrahydro-3ah-azuleno[8,7-b]furan-9-yl]methyl 2-(4-hydroxyphenyl)acetate
6466-74-6
skg846kj3g ,
unii-skg846kj3g
lactucopicrin3,3a,4,5,9a,9b-hexahydro-4-hydroxy-9-(hydroxymethyl)-6-methyl-3-methyleneazuleno(4,5-b)furan-2,7-dione p-hydroxyphenylacetate hydrate
lactucopicrin (intybin)
Q410052
DTXSID90983277
[(3ar,4s,9as,9br)-4-hydroxy-6-methyl-3-methylidene-2,7-dioxo-4,5,9a,9b-tetrahydro-3ah-azuleno[8,7-b]furan-9-yl]methyl2-(4-hydroxyphenyl)acetate
benzeneacetic acid, 4-hydroxy-, (2,3,3a,4,5,7,9a,9b-octahydro-4-hydroxy-6-methyl-3-methylene-2,7-dioxoazuleno[4,5-b]furan-9-yl)methyl ester, [3ar-(3aalpha,4alpha,9aalpha,9bbeta)]-

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (15.38)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.69)	29.6817
2010's	3 (23.08)	24.3611
2020's	7 (53.85)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
sesquiterpenes	[no description available]	medium	15
lactucin	[no description available]	medium	5	azulenofuran; cyclic terpene ketone; enone; primary alcohol; secondary alcohol; sesquiterpene lactone	antimalarial; plant metabolite; sedative
phorbols	[no description available]	medium	5	diterpene; terpenoid fundamental parent
ethylene dimethacrylate	[no description available]	medium	1	enoate ester	allergen; cross-linking reagent; polymerisation monomer
4-vinylpyridine	[no description available]	medium	1
scopolamine hydrobromide	[no description available]	medium	1

Condition	Relationship Strength	Studies
Ache	low	1
Astrocytoma, Grade IV	low	1
Atherogenesis	low	1
Atheroma	low	1
Atheromatous Plaque	low	1
Atheromatous Plaques	low	1
Atherosclerosis	low	1
Atherosclerotic Plaque	low	1
Atherosclerotic Plaques	low	1
Blood Poisoning	low	1
Bloodstream Infection	low	1
Fatty Liver, Nonalcoholic	low	1
Fatty Streak, Arterial	low	1
Fibroatheroma	low	1
Fibroatheromatous Plaques	low	1
Giant Cell Glioblastoma	low	1
Glioblastoma	low	1
Glioblastoma Multiforme	low	1
Inflammation	low	2
Innate Inflammatory Response	low	2
NAFLD	low	1
Non-alcoholic Fatty Liver Disease	low	1
Nonalcoholic Fatty Liver Disease	low	1
Nonalcoholic Steatohepatitis	low	1
Pain	low	1
Pain, Burning	low	1
Pain, Crushing	low	1
Pain, Migratory	low	1
Pain, Radiating	low	1
Pain, Splitting	low	1
Plaque, Atherosclerotic	low	1
Poisoning, Blood	low	1
Pyaemia	low	1
Pyemia	low	1
Pyohemia	low	1
Sepsis	low	1
Septicemia	low	1
Severe Sepsis	low	1
Suffering, Physical	low	1

Article	Year
Lactucopicrin ameliorates oxidative stress mediated by scopolamine-induced neurotoxicity through activation of the NRF2 pathway. Neurochemistry international, Volume: 99	2016
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]